Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets

Simple Summary Recently, our understanding of PFK-2 isozymes, particularly with regards to their roles in cancer, has developed significantly. This review aims to compile the most crucial achievements in this field. Due to the prevailing number of recent studies on PFKFB3 and PFKFB4, we mainly focused on these two isozymes. Here, we comprehensively describe the discoveries and observations to date related to the genetic basis, regulation of expression, and protein structure of PFKFB3/4 and discuss the functional involvement in tumor progression, metastasis, angiogenesis, and autophagy. Furthermore, we highlight crucial studies on targeting PFKFB3 and PFKFB4 for future cancer therapy. This review offers a cutting-edge condensed outline of the significance of specific PFK-2 isozymes in malignancies and can be helpful in understanding past discoveries and planning novel research in this field. Abstract Glycolysis is a crucial metabolic process in rapidly proliferating cells such as cancer cells. Phosphofructokinase-1 (PFK-1) is a key rate-limiting enzyme of glycolysis. Its efficiency is allosterically regulated by numerous substances occurring in the cytoplasm. However, the most potent regulator of PFK-1 is fructose-2,6-bisphosphate (F-2,6-BP), the level of which is strongly associated with 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase activity (PFK-2/FBPase-2, PFKFB). PFK-2/FBPase-2 is a bifunctional enzyme responsible for F-2,6-BP synthesis and degradation. Four isozymes of PFKFB (PFKFB1, PFKFB2, PFKFB3, and PFKFB4) have been identified. Alterations in the levels of all PFK-2/FBPase-2 isozymes have been reported in different diseases. However, most recent studies have focused on an increased expression of PFKFB3 and PFKFB4 in cancer tissues and their role in carcinogenesis. In this review, we summarize our current knowledge on all PFKFB genes and protein structures, and emphasize important differences between the isoenzymes, which likely affect their kinase/phosphatase activities. The main focus is on the latest reports in this field of cancer research, and in particular the impact of PFKFB3 and PFKFB4 on tumor progression, metastasis, angiogenesis, and autophagy. We also present the most recent achievements in the development of new drugs targeting these isozymes. Finally, we discuss potential combination therapies using PFKFB3 inhibitors, which may represent important future cancer treatment options.

[1]  Tingting Liu,et al.  PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships. , 2020, European journal of medicinal chemistry.

[2]  J. Kulbacka,et al.  3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells , 2020, AntiCancer Research.

[3]  Patrick Aloy,et al.  A reference map of the human binary protein interactome , 2020, Nature.

[4]  D. Lin,et al.  Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming , 2020, Nature Communications.

[5]  Siyuan Chen,et al.  PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer , 2020, Development, growth & differentiation.

[6]  R. Shao,et al.  Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism , 2018, BMC Ophthalmology.

[7]  K. Kocemba-Pilarczyk,et al.  The influence of PFK-II overexpression on neuroblastoma patients’ survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4 , 2019, Cancer Cell International.

[8]  Wancai Yang,et al.  PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells , 2019, International journal of molecular sciences.

[9]  J. Molina,et al.  PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses , 2019, Cell Death & Disease.

[10]  R. Houtkooper,et al.  The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis , 2019, Scientific Reports.

[11]  Jenny C. Chang,et al.  Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression , 2019, Nature Communications.

[12]  Y. You,et al.  Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma. , 2019, International journal of clinical and experimental pathology.

[13]  Xin Hu,et al.  High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer , 2019, Cancer Cell International.

[14]  T. Su,et al.  Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis , 2019, Current Medical Science.

[15]  J. Chesney,et al.  Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non–small cell lung cancer cell survival , 2019, The Journal of Biological Chemistry.

[16]  J. Chesney,et al.  Inhibition of glucose metabolism through treatment of BRAF mutated metastatic melanoma with vemurafenib. , 2019, Journal of Clinical Oncology.

[17]  Jinhua Zhang,et al.  mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy , 2019, International journal of molecular sciences.

[18]  Wei Wang,et al.  FOXA1 reprograms the TGF-β-stimulated transcriptional program from a metastasis promoter to a tumor suppressor in nasopharyngeal carcinoma. , 2019, Cancer letters.

[19]  C. Powell,et al.  Global Epidemiology of Lung Cancer , 2019, Annals of global health.

[20]  A. Pawlik,et al.  CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy , 2018, Expert opinion on investigational drugs.

[21]  M. Yi,et al.  6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer , 2018, Molecular metabolism.

[22]  A. Khurana,et al.  Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers , 2018, International journal of cancer.

[23]  D. Stupack,et al.  CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism , 2018, Theranostics.

[24]  Weijun Su,et al.  PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner , 2018, Cellular Physiology and Biochemistry.

[25]  F. Minutolo,et al.  An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade , 2018, ChemMedChem.

[26]  T. Helleday,et al.  Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination , 2018, Nature Communications.

[27]  S. Ghavami,et al.  Association of single nucleotide autophagy‐related protein 5 gene polymorphism rs2245214 with susceptibility to non–small cell lung cancer , 2018, Journal of cellular biochemistry.

[28]  R. Bartrons,et al.  Fructose 2,6-Bisphosphate in Cancer Cell Metabolism , 2018, Front. Oncol..

[29]  Wei Wang,et al.  Dual-functionality of RASSF1A overexpression in A375 cells is mediated by activation of IL-6/STAT3 regulatory loop , 2018, Molecular Biology Reports.

[30]  R. Bartrons,et al.  The potential utility of PFKFB3 as a therapeutic target , 2018, Expert opinion on therapeutic targets.

[31]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[32]  L. Gaboury,et al.  RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma. , 2018, Cancer research.

[33]  S. Ghavami,et al.  Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells. , 2018, Biochimica et biophysica acta. Molecular cell research.

[34]  Alan Morris.  Inhibiting glycolysis in tumour cells , 2018, Nature Reviews Endocrinology.

[35]  A. Hjelmeland,et al.  The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[36]  Quan Gao,et al.  PFK15, a PFKFB3 antagonist, inhibits autophagy and proliferation in rhabdomyosarcoma cells , 2018, International journal of molecular medicine.

[37]  K. Rajapakshe,et al.  Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer , 2018, Nature.

[38]  Xiao-dong Zhu,et al.  PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT , 2018, Cell Death & Disease.

[39]  Huapeng Li,et al.  Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor , 2018, Oncogene.

[40]  Qiang Li,et al.  PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis. , 2018, International journal of oncology.

[41]  Z. Ling,et al.  Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis , 2018, Nature Communications.

[42]  A. Seyfoori,et al.  Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response , 2017, Pharmacology & therapeutics.

[43]  Jianguo Zhang,et al.  Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy , 2018, Molecular and Cellular Biochemistry.

[44]  Xiaoming Fan,et al.  By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma , 2017, International journal of cancer.

[45]  Yanqin Sun,et al.  Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy , 2017, Clinical Cancer Research.

[46]  H. Pan,et al.  Roles of PFKFB3 in cancer , 2017, Signal Transduction and Targeted Therapy.

[47]  Liang Han,et al.  PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma , 2017, Journal of Cancer.

[48]  Anna M. Ritz,et al.  Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade , 2017, Genes & development.

[49]  Xuejun Jiang,et al.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 spatially mediates autophagy through the AMPK signaling pathway , 2017, Oncotarget.

[50]  I. Vhora,et al.  Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer , 2017, Pharmaceutical Research.

[51]  P. Carmeliet,et al.  Tumor vessel disintegration by maximum tolerable PFKFB3 blockade , 2017, Angiogenesis.

[52]  Yu Zhu,et al.  The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer , 2017, Oncotarget.

[53]  D. Vertommen,et al.  Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes. , 2017, Cellular signalling.

[54]  N. Ferri,et al.  The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1 , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[55]  Liling Qian,et al.  CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4 , 2017, Oncotarget.

[56]  A. Yalçin,et al.  6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is required for transforming growth factor β1-enhanced invasion of Panc1 cells in vitro. , 2017, Biochemical and biophysical research communications.

[57]  Marek J. Łos,et al.  New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets , 2017, Autophagy.

[58]  Yonghuai Feng,et al.  mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival. , 2017, Biochemical and biophysical research communications.

[59]  R. Bast,et al.  Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells , 2017, Oncotarget.

[60]  Hui-min Li,et al.  Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma , 2017, Journal of experimental & clinical cancer research : CR.

[61]  Yong-Hwan Lee,et al.  Crystal structure of heart 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase (PFKFB2) and the inhibitory influence of citrate on substrate binding , 2017, Proteins.

[62]  P. Carmeliet,et al.  Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy. , 2016, Cancer cell.

[63]  Marek J. Łos,et al.  Photodynamic N-TiO2 Nanoparticle Treatment Induces Controlled ROS-mediated Autophagy and Terminal Differentiation of Leukemia Cells , 2016, Scientific Reports.

[64]  P. Yu,et al.  PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer , 2016, PloS one.

[65]  J. Chesney,et al.  Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer , 2016, Breast Cancer Research and Treatment.

[66]  P. Liu,et al.  Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment. , 2016, Oncology reports.

[67]  M. Lea,et al.  Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3. , 2016, Anticancer research.

[68]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[69]  G. Christofori,et al.  Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy , 2015, Cell reports.

[70]  Sangeeta Khare,et al.  Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition) , 2016 .

[71]  Cell Cancer.  Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy. , 2016 .

[72]  Q. Ding,et al.  Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer. , 2016, International journal of oncology.

[73]  W. Zheng,et al.  MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression. , 2015, Genetics and molecular research : GMR.

[74]  Xuejun Jiang,et al.  Akt inhibition attenuates rasfonin-induced autophagy and apoptosis through the glycolytic pathway in renal cancer cells , 2015, Cell Death and Disease.

[75]  M. Lea,et al.  Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. , 2015, Anticancer research.

[76]  B. O’Malley,et al.  Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug , 2015, PloS one.

[77]  M. Malumbres,et al.  AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest , 2015, Nature Cell Biology.

[78]  J. Rzeszowska-Wolny,et al.  The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells , 2015, Oncotarget.

[79]  Yuanting Gu,et al.  Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. , 2015, Biochemical and biophysical research communications.

[80]  J. Trent,et al.  Abstract 4478: 6-Phosphofructo-2-Kinase (PFKFB3): At the crossroads of resistance to targeted cancer therapies , 2015 .

[81]  C. Ward,et al.  A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models , 2015, Oncotarget.

[82]  J. Trent,et al.  Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor , 2015, Oncotarget.

[83]  J. Debreczeni,et al.  Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. , 2015, Journal of medicinal chemistry.

[84]  Lie-dao Yu,et al.  miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells. , 2015, Oncology reports.

[85]  J. Rathmell,et al.  Novel Therapeutic Targets of Tumor Metabolism , 2015, Cancer journal.

[86]  D. Sabatini,et al.  Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB4) as a Novel Autophagy Regulator by High Content shRNA Screening , 2015, Oncogene.

[87]  H. Esumi,et al.  Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. , 2014, World journal of gastroenterology.

[88]  A. Lane,et al.  Fructose-2,6-Bisphosphate synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth , 2014, Oncotarget.

[89]  M. Ciriolo,et al.  MAPK14/p38α-dependent modulation of glucose metabolism affects ROS levels and autophagy during starvation , 2014, Autophagy.

[90]  Yunchao Su,et al.  Endothelial PFKFB3 Plays a Critical Role in Angiogenesis , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[91]  J. Chesney,et al.  Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib , 2014, Cancer & Metabolism.

[92]  M. Ohmura,et al.  Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway , 2014, Nature Communications.

[93]  J. Chesney,et al.  Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3)* , 2014, The Journal of Biological Chemistry.

[94]  C. Weyand,et al.  The glycolytic enzyme PFKFB3/phosphofructokinase regulates autophagy , 2014, Autophagy.

[95]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[96]  J. Chesney,et al.  Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism , 2014, Cancer & metabolism.

[97]  D. Klionsky,et al.  An overview of autophagy: morphology, mechanism, and regulation. , 2014, Antioxidants & redox signaling.

[98]  P. Carmeliet,et al.  Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. , 2014, Cell metabolism.

[99]  T. Hagen,et al.  Increased Concentrations of Fructose 2,6-Bisphosphate Contribute to the Warburg Effect in Phosphatase and Tensin Homolog (PTEN)-deficient Cells* , 2013, The Journal of Biological Chemistry.

[100]  C. Weyand,et al.  Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells , 2013, The Journal of experimental medicine.

[101]  P. Carmeliet,et al.  Role of PFKFB3-Driven Glycolysis in Vessel Sprouting , 2013, Cell.

[102]  J. Trent,et al.  Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer , 2013, Molecular Cancer Therapeutics.

[103]  J. Chesney,et al.  Regulation of glycolytic and mitochondrial metabolism by ras. , 2013, Current pharmaceutical biotechnology.

[104]  A. Schulze,et al.  Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism , 2013, Cancer & Metabolism.

[105]  Wun-Jae Kim,et al.  PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. , 2012, Urologic oncology.

[106]  G. Reifenberger,et al.  RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival , 2012, Oncogene.

[107]  R. Burd,et al.  Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH. , 2012, Translational oncology.

[108]  M. Cavalier,et al.  Molecular basis of the fructose‐2,6‐bisphosphatase reaction of PFKFB3: Transition state and the C‐terminal function , 2012, Proteins.

[109]  Gavin Kelly,et al.  Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. , 2012, Cancer discovery.

[110]  J. L. Rosa,et al.  Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells. , 2012, The Biochemical journal.

[111]  O. Abdel-Wahab,et al.  The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity , 2011, Leukemia.

[112]  M. Fleischer,et al.  LOH on 10p14‐p15 targets the PFKFB3 gene locus in human glioblastomas , 2011, Genes, chromosomes & cancer.

[113]  Y. Bae,et al.  Block Copolymer Micelles for Controlled Delivery of Glycolytic Enzyme Inhibitors , 2011, Pharmaceutical Research.

[114]  Yong-Hwan Lee,et al.  Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect , 2011, PloS one.

[115]  Martin Enge,et al.  Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53 , 2011, The Journal of Biological Chemistry.

[116]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[117]  Chi V. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[118]  M. Demirci.  Comprehensive Clinical Nephrology 3rd Edition , 2011 .

[119]  Jong-Seok Moon,et al.  Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. , 2011, The Biochemical journal.

[120]  R. Bartrons,et al.  Fructose 2,6-bisphosphate: the last milestone of the 20th century in metabolic control? , 2010 .

[121]  W. Chazin,et al.  S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3 , 2010, Cell Research.

[122]  F. Bleichert,et al.  The PFKFB3 splice variant UBI2K4 is downregulated in high‐grade astrocytomas and impedes the growth of U87 glioblastoma cells , 2009, Neuropathology and applied neurobiology.

[123]  A. Yalçin,et al.  Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. , 2009, Experimental and molecular pathology.

[124]  A. Lane,et al.  Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases* , 2009, The Journal of Biological Chemistry.

[125]  J. Klawitter,et al.  Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells , 2009, Clinical Cancer Research.

[126]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[127]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[128]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[129]  W. Chazin,et al.  S 100 A 8 / A 9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP 3 , 2009 .

[130]  H. Esumi,et al.  Alternative splice variants of rat 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-4 mRNA. , 2008, Ukrains'kyi biokhimichnyi zhurnal.

[131]  R. Singh,et al.  Tumor angiogenesis--a potential target in cancer chemoprevention. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[132]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[133]  F. Bleichert,et al.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas , 2008, Journal of Neuro-Oncology.

[134]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[135]  A. Lane,et al.  Ras transformation requires metabolic control by 6-phosphofructo-2-kinase , 2006, Oncogene.

[136]  J. Chesney.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis , 2006, Current opinion in clinical nutrition and metabolic care.

[137]  R. Bartrons,et al.  PFKFB3 gene silencing decreases glycolysis, induces cell‐cycle delay and inhibits anchorage‐independent growth in HeLa cells , 2006, FEBS letters.

[138]  Yong-Hwan Lee,et al.  Crystal Structure of the Hypoxia-inducible Form of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) , 2006, Journal of Biological Chemistry.

[139]  H. Esumi,et al.  Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. , 2006, Acta biochimica Polonica.

[140]  H. Esumi,et al.  Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. , 2005, Biochimie.

[141]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[142]  D. Gilliland,et al.  The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. , 2005, Mayo Clinic proceedings.

[143]  N. Manes,et al.  The kinase activity of human brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is regulated via inhibition by phosphoenolpyruvate. , 2005, Archives of biochemistry and biophysics.

[144]  N. Amariglio,et al.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. , 2005, Cancer research.

[145]  R. Bartrons,et al.  Specific expression of pfkfb4 gene in spermatogonia germ cells and analysis of its 5′‐flanking region , 2005, FEBS letters.

[146]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[147]  D. Vertommen,et al.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. , 2004, The Biochemical journal.

[148]  Geoffrey J. Barton,et al.  The Jalview Java alignment editor , 2004, Bioinform..

[149]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[150]  J. Caro,et al.  Hypoxic regulation of the 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase gene family (PFKFB‐1–4) expression in vivo , 2003, FEBS letters.

[151]  K. Uyeda,et al.  Tissue-specific Structure/Function Differentiation of the Liver Isoform of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase* , 2003, The Journal of Biological Chemistry.

[152]  L. Leng,et al.  High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. , 2002, Cancer research.

[153]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[154]  N. Savaraj,et al.  Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.

[155]  R. Bartrons,et al.  PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. , 2001, Trends in biochemical sciences.

[156]  D. Carling,et al.  Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia , 2000, Current Biology.

[157]  M. Devany,et al.  Mechanism of the bisphosphatase reaction of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase probed by (1)H-(15)N NMR spectroscopy. , 2000, Biochemistry.

[158]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[159]  H. Mizuguchi,et al.  A switch in the kinase domain of rat testis 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. , 1999, Biochemistry.

[160]  R. Bucala,et al.  An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[161]  H. Mizuguchi,et al.  Crystal Structure of the H256A Mutant of Rat Testis Fructose-6-phosphate,2-kinase/Fructose-2,6-bisphosphatase , 1999, The Journal of Biological Chemistry.

[162]  J L Sussman,et al.  Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. , 1998, Acta crystallographica. Section D, Biological crystallography.

[163]  D. Heine-Suñer,et al.  Sequence and structure of the human 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase heart isoform gene (PFKFB2). , 1998, European journal of biochemistry.

[164]  R. Sakakibara,et al.  Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. , 1997, Journal of biochemistry.

[165]  M. Watanabe,et al.  Inhibition of fructose-6-phosphate,2-kinase by N-bromoacetylethanolamine phosphate in vitro and in vivo. , 1997, Journal of biochemistry.

[166]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[167]  K. Uyeda,et al.  Hexose phosphate binding sites of fructose 6-phosphate,2-kinase:fructose 2,6-bisphosphatase. , 1995, Biochemistry.

[168]  I. Kurland,et al.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a metabolic signaling enzyme. , 1995, Annual review of biochemistry.

[169]  F. C. Hartman,et al.  Hexose phosphate binding sites of fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. Interaction with N-bromoacetylethanolamine phosphate and 3-bromo-1,4-dihydroxy-2-butanone 1,4-bisphosphate. , 1984, The Journal of biological chemistry.

[170]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[171]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.